Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Daraxonrasib and the era of pan-RAS inhibition: mechanisms, clinical advances, and resistance landscapes

Activating RAS mutations drive a substantial proportion of human cancers, yet for decades RAS was considered undruggable. The recent development of tri-complex inhibitors (TCIs) such as daraxonrasib (RMC-6236) has transformed the therapeutic landscape by enabling potent, multi-selective targeting of the active, GTP-bou...

Jiacheng Lou, Dan Zhang · 0 citations
Review Open access Aug 2026

Protein farnesylation: from molecular mechanisms to therapeutic targeting in cancer, aging, and beyond

Protein farnesylation, catalyzed by farnesyltransferase (FTase), covalently attaches a 15-carbon farnesyl lipid to cysteine residues within C-terminal CaaX motifs. This modification governs the subcellular localization, protein–protein interactions, and activity of diverse eukaryotic proteins, including Ras GTPases, nu...

Jiacheng Lou, Dan Zhang, Ying-Jie Wang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.